GTX Inc (NASDAQ:GTXI)

Add to Watch List
Set Alert
17.39
Delayed Data
As of Apr 23
 +0.27 / +1.58%
Today’s Change
2.73
Today|||52-Week Range
23.40
+36.82%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$463.2M

Company Description

GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

Contact Information

GTx, Inc.
175 Toyota Plaza
Memphis Tennessee 38103
P:(901) 523-9700
Investor Relations:

Employees

Shareholders

Other institutional8.22%
Mutual fund holders6.34%
Individual stakeholders33.69%

Top Executives

Marc Steven HanoverChief Executive Officer & Director
Jason T. ShackelfordPrincipal Financial & Accounting Officer
Mary Ann JohnstonVice President-Clinical Development
Diane C. YoungChief Medical Officer & Vice President
Henry Patton DoggrellSecretary, Chief Legal Officer & Vice President